Feature: From breakthrough to bedside: closing the myeloma delivery gap in the NHS
24 July, 2025
The treatment landscape for multiple myeloma is changing fast, and for the better. For patients who have relapsed or exhausted their options, there is now a renewed sense of hope. Chimeric Antigen Receptor Therapies (CAR-T) and bispecific antibodies (BsAbs) are transforming outcomes in ways that were once unimaginable. Trispecific antibodies (TsAbs) are already in early clinical development, offering a further evolution by either targeting multiple myeloma-associated antigens simultaneously or helping prevent T-cell exhaustion. We are witnessing some of the most significant breakthroughs in blood cancer treatment in decades.
While therapeutics for multiple myeloma are accelerating, our health system is struggling to keep up. The reality on the ground is that these therapies, particularly CAR-T and BsAbs, introduce significant operational pressures into a healthcare system already stretched to its limits. Even though BsAbs offer the advantage of being “off the shelf,” the profile of their side effects, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), often requires patients to be closely monitored in inpatient settings. This can create a logistical bottleneck for hospitals that are already managing high bed occupancy, workforce constraints, and increasing clinical complexity.
What we’re seeing now is not just a question of adoption, but of integration. How do we enable these therapies to reach the patients who need them most, without compromising safety or widening access inequalities? How do we ensure the system is not just receptive to innovation, but actually built to deliver it?
From Policy to Practice: Accelerating Digital Health MM Infrastructures to Deliver on the NHS 10 Year Plan
The NHS 10-Year Plan sets out a clear objective: to move care into the community, reduce reliance on hospital beds, and adopt digital tools that support earlier intervention. This vision aligns with the needs of advanced therapies, but implementation remains slow. New models of care require more than clinical evidence. They need the right infrastructure, data systems, and governance to support delivery at scale.
Digital tools must now be considered part of the treatment pathway. Remote monitoring, wearable devices, and real-time patient-reported data can reduce inpatient stays, flag deterioration early, and support decision-making. These technologies already exist and are being used successfully in rare disease programmes. The NHS 10-Year Plan calls for more personalised, preventative, and digitally enabled care delivered closer to home. These tools must now be applied to oncology in a consistent and safe way to meet that ambition.
Sanius Health is working closely with clinical and research teams to better understand the real-world impact of new therapeutics and models of care on patients with multiple myeloma. By capturing continuous, wearable-derived data, including activity levels, sleep quality, heart rate, respiratory rate, and SpO₂, the company is building a richer picture of how patients respond to treatment outside of traditional care settings. This approach supports more personalised, preventative, and proactive care, in line with the NHS 10-Year Plan. It enables earlier identification of deterioration, improved treatment planning, and a shift towards delivering high-quality care closer to home.
As a system, we might have clear ambitions for innovation and digital transformation, but it is essential that clinicians lead the process. Their insight and leadership ensure that new models of care are grounded in clinical realities and patient safety. Technology must support the way care is delivered, not disrupt it. Safety cannot be compromised, but progress cannot be delayed. The pipeline for oncology and haematology is expanding. CAR-T, tumour-infiltrating lymphocytes, and trispecifics are all advancing, and many will require the same level of monitoring and structured delivery as current myeloma treatments.
Sanius’s deep engagement with patients across its ecosystem, alongside clinicians, and research partners has shaped both our understanding and our commitment to supporting this shift. It drives our motivation to build an ecosystem that enables safe, scalable, and patient-led adoption of advanced therapies, underpinned by the digital infrastructure required to deliver it effectively.
To learn more about our work in supporting clinical and research activity across multiple myeloma and other haematological malignancies, visit: www.saniushealth.com or get in touch: info@saniushealth.com
